Multiple Sclerosis Drugs - Bahrain

Bahrain

Highlights

The Multiple Sclerosis Drugs market in Bahrain is projected to generate a revenue of US$3.01m by 2024.
This represents a significant growth potential for the market.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.14%, resulting in a market volume of US$3.18m by 2029.
In terms of global comparison, United States is expected to dominate the market, generating a revenue of US$11.77bn by 2024.
This highlights the significant market size and potential United States compared to other countries.
Bahrain's market for Multiple Sclerosis Drugs is witnessing an increasing demand for innovative treatments and personalized medicine.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Multiple Sclerosis (MS) is a chronic disease that affects the central nervous system, and the demand for MS drugs has been increasing in Bahrain over the past few years.

Customer preferences: Patients with MS in Bahrain prefer disease-modifying therapies (DMTs) to manage their condition. The preference for DMTs is due to their effectiveness in reducing the frequency and severity of relapses and slowing the progression of the disease. Patients also prefer DMTs because they have fewer side effects compared to other treatments.

Trends in the market: The MS drugs market in Bahrain is expected to grow in the coming years due to the increasing prevalence of MS in the country. The number of MS cases in Bahrain has been increasing steadily over the past few years, and this trend is expected to continue. Additionally, the introduction of new drugs and therapies in the market is expected to drive growth in the MS drugs market in Bahrain.

Local special circumstances: Bahrain has a high prevalence of MS compared to other countries in the region. The exact reason for this is unknown, but it is thought to be due to a combination of genetic and environmental factors. The government of Bahrain provides free healthcare to all citizens and residents, which has contributed to the high demand for MS drugs in the country.

Underlying macroeconomic factors: Bahrain has a small population, and the healthcare sector is dominated by private providers. The government is working to increase access to healthcare services, and this is expected to drive growth in the healthcare sector in the coming years. Additionally, Bahrain has a high-income economy, and this has contributed to the high demand for MS drugs in the country. In conclusion, the MS drugs market in Bahrain is expected to grow in the coming years due to the increasing prevalence of MS in the country and the introduction of new drugs and therapies in the market. Patients in Bahrain prefer DMTs to manage their condition, and the government's provision of free healthcare has contributed to the high demand for MS drugs in the country. The underlying macroeconomic factors, including Bahrain's small population and high-income economy, are also expected to drive growth in the MS drugs market in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.